About
The Outcome Measures in Rheumatology (OMERACT) synovial tissue biopsy (STB) working group initiated an international effort to standardize STB analyses, define consensual items to inform treatment choices, and predict responses in rheumatoid arthritis (RA).
Six markers were identified for examination in a multicenter study designed to define an OMERACT-endorsed set of STB markers to predict responses to treatment.
Current Stage in the OMERACT Process
The group is standardizing biopsy markers that may help predict treatment response in RA. Consensus scoring and data analysis are nearing completion.
Latest Update
OMERACT 2025 Conference Highlights
Fellow Poster: Our OMERACT Fellow, Mario Ferraioli, presented a poster summarizing the current state of our work, sparking excellent conversations about next steps and collaborations.
View the poster here
Lightning Talk: In a rapid-fire session, our team shared an upcoming teaser of the Special Interest Group (SIG) session taking place during the conference.
Watch the lightning talk here
Closing Plenary Talk: We were also featured in the Closing Plenary, where we highlighted the activities of the (SIG).
Watch the presentation here
Next Meeting
TBD
Meet the Team
Aurelie Najm, Ireland
Chair
Mihir Wechalekar, Australia
Chair
Vibeke Strand, USA
Chair
Mario Ferraioli, Italy
Emerging Leader
Recent Publications
- Wechalekar, Mihir D., et al. “The 2018 OMERACT Synovial Tissue Biopsy Special Interest Group Report on Standardization of Synovial Biopsy Analysis.” Journal of Rheumatology, vol. 46, no. 10, 2019, pp. 1365–68, https://doi.org/10.3899/jrheum.181062.